Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor. Favorable results from a Phase II trial of infigratinib in advanced/metastatic -altered cholangiocarcinomas has led to its further investigation in the front-line setting. In this article we describe the design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, randomized trial of infigratinib in comparison to standard of care gemcitabine and cisplatin in advanced/metastatic cholangiocarcinoma with translocations. The results of this study have the potential to define a new role for a chemotherapy-free, targeted therapy option in the front-line setting for these patients. Clinical Trial Registration: NCT03773302 (ClincalTrials.gov).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2020-0299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Electronic decision aids enhance management of primary care patients with steatotic liver disease: Proof of concept pilot study.
Hepatol Commun
September 2025
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: The approach to appropriate risk stratification for metabolic dysfunction-associated steatotic liver disease (MASLD) is variable, and the adoption of non-invasive liver disease assessments in clinical practice is suboptimal. In this study, we implemented an electronic decision support tool for primary care patients with MASLD to assess its influence on linkage to care.
Methods: We performed a prospective, before-and-after pilot study in which post-implementation providers were presented with an electronic decision aid automating non-invasive liver disease assessments with the Fibrosis-4 score and providing individualized, guideline-directed recommendations.
Epoxy-Ether Network Binder Empowers Ultra-High Sulfur Loading in Practical Lithium-Sulfur Batteries.
Small
August 2025
Key Lab for Special Functional Materials of Ministry of Education, National; Local Joint Engineering Research Center for High-efficiency Display and Lighting Technology, School of Materials Science and Engineering, Collaborative Innovation Center of Nano Functional Materials and Applications, Henan
Achieving high energy density and long-term cycling stability in lithium-sulfur (Li-S) batteries under practical conditions, namely high sulfur loading (≥ 5 mg cm) and lean electrolyte content (E/S ratio < 5 µL mg), remains a formidable challenge due to severe volume expansion, interfacial instability, and polysulfide shuttling. Herein, a rationally designed 3D cross-linked polyether binder (PTPO) is reported, synthesized via cationic copolymerization of glycerol triglycidyl ether (TEP) and 1,3-dioxolane (DOL). This multifunctional binder integrates high mechanical flexibility, superior interfacial adhesion, and strong chemical affinity toward lithium polysulfides through its abundant ether linkages and epoxy groups.
View Article and Find Full Text PDFMyeloid loss of scaffolding protein menin promotes liver fibrosis via H3K36me3 reprogramming.
J Biol Chem
August 2025
Department of Basic Medical Sciences, School of Medicine, Xiamen University; Xiamen, China. Electronic address:
Menin, encoded by the Men1 gene, is a scaffold protein broadly involved in regulating the cell phenotype through multiple histone modifications. Here, we discuss how menin contributes to liver macrophage (MAC) and hepatic stellate cell (HSC) fate determination, placing this contribution in the context of liver fibrosis pathogenesis. We revealed that Men1 loss promoted CCL4- or high-fat diet-induced liver fibrosis.
View Article and Find Full Text PDFAutomated tick classification using deep learning and its associated challenges in citizen science.
Sci Rep
July 2025
School of Information Technology, Halmstad University, 301 18, Halmstad, Sweden.
Lyme borreliosis and tick-borne encephalitis significantly impact public health in Europe, transmitted primarily by endemic tick species. The recent introduction of exotic tick species into northern Europe via migratory birds, imported animals, and travelers highlights the urgent need for rapid detection and accurate species identification. To address this, the Swedish Veterinary Agency launched a citizen science initiative, resulting in the submission of over 15,000 tick images spanning seven species.
View Article and Find Full Text PDFSystemically delivered lipid nanoparticle-mRNA encoding lysosomal acid β-glucosidase restores the enzyme deficiency in a murine Gaucher disease model.
Gene Ther
July 2025
Immorna (Hangzhou) Biotechnology, Co. Ltd., Hangzhou, Zhejiang, China.
Gaucher disease (GD) is a rare genetically inherited illness caused by loss of lysosomal acid β-glucosidase (β-GCase) that leads to progressive accumulation of substrates, sphingolipid glucosylceramide (GL1) and glucosylsphingosine (lyso-GL1). The protein-based enzyme replacement therapy (ERT) requires frequent dosing due to short drug half-life causing challenges in long-term patient compliance. JCXH-301 is a lipid nanoparticle (LNP) encapsulated messenger RNA (mRNA) encoding β-GCase.
View Article and Find Full Text PDF